Low-molecular-weight heparins in coronary stenting (The ENTICES trial)

American Journal of Cardiology

Volumn 82, Issue 5 B, 1998, Pages 29L-32L

  Zidar, James P ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; DEXTRAN; DIPYRIDAMOLE; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; TICLOPIDINE; WARFARIN;

ADULT; ANTICOAGULANT THERAPY; BLEEDING; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STENT; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOSIS; THROMBOSIS PREVENTION; TREATMENT OUTCOME;

EID: 0032504924     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(98)00110-6     Document Type: Conference Paper

References (9)

1. Tanguay JF, Crowley JJ, Kruse KR, Armstrong BA, Santos RM, Zidar JP, Virmani R, Phillips HP, Stack RS. Antiplatelet versus warfarin therapy: platelet, neutrophil, and thrombus deposition for intracoronary stents in a procine model. J Interven Cardiol 1997;349-56.
2. Barragan P, Sainsous J, Silvestri M, Bouvier JL, Comet B, Simeoni JB, Charmasson C, Bremondy M. Ticlopidine and subcutaneous heparin as an alternative regimen following coronary stenting. Cathet Cardiovasc Diagn 1994;32: 133-138.
3. Morice MC, Bourdonnec C, Lefevre T, Blanchard D, Monassier J-P, Lienhart Y, Commeau P, Makowski S, Labrunie P, Cribier A, Joly P. Coronary stenting without coumadin. Phase III. (Abstr.) Circulation 1994;90(suppl):I-125.
4. Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I, Detre K, Veltri L, Ricci D, Nobuyoshi M. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med 1994;331:496-501.
5. Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, Emanuelsson H, Marco J, Legrand V, Materne P. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med 1994;331:489-495.
6. Ryan TJ, Faxon DP, Gunnar RM, Kennedy JW, King SB III, Loop FD, Peterson KL, Reeves TJ, Williams DO, Winters WL Jr, Fisch C, DeSanctis RW, Dodge HT, Reeves TJ, Weinberg SL. Guidelines for percutaneous transluminal coronary angioplasty: A report of the American College of Cardiology/American Heart Association Task Force on assessment of diagnostic and therapeutic cardiovascular procedures (subcommittee on percutaneous transluminal coronary angioplasty). J Am Coll Cardiol 1988;12:529-545.
7. Wilson RF, Lesser GR, Laxson DD, White CW. Intense microvascular constriction after angioplasty of acute thrombotic coronary arterial lesions. Lancet 1989:1(8642):807-811.
8. Ferguson JJ, Fox R. Meeting highlights. The 69th Scientific Sessions of the American Heart Association in New Orleans, LA, November 10-13, 1996. Circulation 1997;95:761-764.
9. Data from ATLAST protocol, dated 6/10/97, on file at Rhône-Poulenc Rorer.